Chronic Hepatitis C Virus
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
Published in Hepatitis Weekly, November 16th, 2009
Valeant Pharmaceuticals (NYSE:VRX) announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon, were presented at the American Association for the Study of Liver Disease (AASLD) 60th Annual Meeting in Boston. It is believed that taribavirin (TBV) may present an alternative therapy to ribavirin (RBV) for the treatment of hepatitis C by delivering similar efficacy to ribavirin but with significantly less anemia, which is the main treatment-limiting toxicity associated with ribavirin.
The...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2009-11-16)
More Articles from Hepatitis Weekly
- Henry Ford Health System
Hepatitis B does not increase risk for pancreatic cancer - Hepatitis
Studies from S.K. Roberts et al add new findings in the area of hepatitis - Hepatitis C Virus
New hepatitis C virus research has been reported by scientists at Massachusetts General Hospital - Hepatitis C Virus
Reports from H.S. Ol and co-researchers add new data to research in hepatitis C virus - Hepatitis C Virus
Study results from Mayo Clinic update understanding of hepatitis C virus - Hepatocellular Cancer
Research on hepatocellular cancer discussed by A. Cavazza and co-researchers - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
